Company Profile
Vistagen Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- VTGN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.28 USD (-4.44%)
Close
Last updated: August 6, 2026
23M USD
Market cap
Why the stock is moving
Following the latest company update, “Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder”, VTGN closed down 4.44% at $0.2838 on Aug 6, 2026. The move occurred in the trading session associated with this clinical readout update.
Company overview
Business overview
Vistagen Therapeutics is a neuroscience company focused on intranasal therapies for anxiety, depression, and related psychiatric conditions. Its story is built around trying to create faster-acting or better-tolerated treatments in mental health.
Geographic Base and Sector Classification
Vistagen is headquartered in the United States and listed on NASDAQ, with a development-stage neuroscience profile. It sits in the small-cap CNS biotech category.
Business Model Characteristics
The company depends on clinical data, regulatory strategy, and proof that its intranasal approach can differentiate itself in psychiatry. Investors usually watch trial readouts, safety, and path-to-market decisions.
Position Within the Biotechnology Landscape
Vistagen occupies a high-catalyst CNS biotech niche. The stock tends to move on clinical evidence and the market's belief in whether the platform can address unmet psychiatric need.
Future catalysts
Vistagen’s catalysts are PH94B and the social-anxiety / depression programs, where clinical and regulatory updates can materially move the stock. The company is still very much a data story.
Recent news
- 01
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Source: Vistagen Therapeutics, Inc.
- 02
Vistagen Appoints Douglas J. Williamson to its Board of Directors
Source: Vistagen Therapeutics, Inc.
- 03
VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference
Source: Vistagen Therapeutics, Inc.
- 04
VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
Source: Vistagen Therapeutics, Inc.
- 05
VistaGen Therapeutics to Report Fiscal Year 2022 Third Quarter Financial Results on February 10, 2022
Source: Vistagen Therapeutics, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Vistagen Therapeutics, Inc. (VTGN)?
Vistagen Therapeutics, Inc. (VTGN) most recently closed at 0.28 USD, a -4.44% move versus the previous session.
What is the market cap of Vistagen Therapeutics, Inc. (VTGN)?
Vistagen Therapeutics, Inc. currently has a market capitalization of 23M USD on BioPharmSignal.
What does Vistagen Therapeutics, Inc. do?
Vistagen Therapeutics is a neuroscience company focused on intranasal therapies for anxiety, depression, and related psychiatric conditions. Its story is built around trying to create faster-acting or better-tolerated treatments in mental health.
On which exchange is VTGN stock listed?
Vistagen Therapeutics, Inc. (VTGN) is associated with NASDAQ, United States, Biopharma.
What is Vistagen?
Vistagen’s catalysts are PH94B and the social-anxiety / depression programs, where clinical and regulatory updates can materially move the stock.
Which conditions is Vistagen Therapeutics, Inc. targeting with Vistagen?
Vistagen Therapeutics, Inc. is associated with neuroscience based on its company overview and current catalyst commentary.
How does Vistagen Therapeutics, Inc. describe recent progress with Vistagen?
Vistagen’s catalysts are PH94B and the social-anxiety / depression programs, where clinical and regulatory updates can materially move the stock.
What is Therapeutics?
Vistagen Therapeutics is a neuroscience company focused on intranasal therapies for anxiety, depression, and related psychiatric conditions.